Study ID (Protocol Number)
CA209-039
 
STUDY LOCATIONS*


 




*Not all study site locations may be listed - please check back soon for updated
information. For more information regarding other participating countries, please
visit clinicaltrials.gov.
  STUDY NAME
Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma
STUDY OVERVIEW
The purpose of this study is to determine the side effects of treatment with Nivolumab alone and in combination with Ipilimumab or Lirilumab in subjects with hematological malignancies and the dose that should be recommended for use in future studies.
 

 
The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.
Find A Study